Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01
June 29th 2020Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.